Libtayo (Cemiplimab)

Cemiplimab is a monoclonal antibody that blocks the PD‑1 receptor on T cells, preventing its interaction with PD‑L1 and PD‑L2 on tumor cells. This blockade releases the inhibitory checkpoint, allowing T cells to remain active and attack cancer cells more effectively.

The dosing regimen for Libtayo is determined by the prescribing oncologist based on the specific indication, patient weight, and clinical factors. Healthcare professionals follow the product’s prescribing information to select the appropriate dose and infusion schedule.

Safety of Libtayo in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To order Libtayo, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Libtayo (cemiplimab) shares the same PD‑1 target as other agents such as pembrolizumab and nivolumab, but it has distinct clinical trial data supporting its use in cutaneous squamous cell carcinoma and certain basal cell carcinomas. Choice of therapy often depends on approved indications, physician experience, and patient‑specific factors.

Libtayo must be stored refrigerated at 2‑8 °C, protected from light. It should not be frozen or shaken. Vials should be kept in their original packaging until use to maintain stability and sterility.

Libtayo is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically administered over a set period according to the prescribing information, and patients are monitored for infusion‑related reactions during and after the procedure.

Serious risks include immune‑mediated pneumonitis, hepatitis, colitis, endocrinopathies (such as thyroiditis or adrenal insufficiency), severe skin reactions, and anaphylaxis. Patients should be educated to report new respiratory symptoms, abdominal pain, severe diarrhea, hormonal changes or any signs of allergic reaction promptly.

Libtayo is contraindicated in patients with known hypersensitivity to cemiplimab or any of its excipients. It should be used with caution in individuals with active autoimmune diseases, uncontrolled infections, or those receiving live vaccines. The prescriber must evaluate each patient’s medical history before initiating therapy.